Seong Lin Khaw

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Andrew J. Souers, Joel D. Leverson, Erwin R. Boghaert et al. · Nature Medicine · 2013 · 3K citations

Medicine, Oncology, Pharmacology +10

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Andrew W. Roberts, John F. Seymour, Jennifer R. Brown et al. · Journal of Clinical Oncology · 2011 · 818 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer

Marie Wong, Chelsea Mayoh, Loretta M. S. Lau et al. · Nature Medicine · 2020 · 404 citations · Full text

Life Sciences, Genetics, Oncology +14

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial

Theodore W. Laetsch, Shannon L. Maude, Susana Rives et al. · Journal of Clinical Oncology · 2022 · 357 citations · Full text

Medicine, Hematology, Oncology +17

Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Vinod Pullarkat, Norman J. Lacayo, Elias Jabbour et al. · Cancer Discovery · 2021 · 288 citations · Full text

Medicine, Oncology, Pharmacotherapy +17